Mylan Acquires Butorphanol Tartrate Nasal Spray.Business Editors PITTSBURGH--(BUSINESS WIRE)--Aug. 14, 2001 Mylan Laboratories Inc. (NYSE NYSE See: New York Stock Exchange :MYL MYL Mind Your Language MYL Made You Laugh MYL Miss You Lots MYL Meet You Later MYL Miss You Loads ) announced today that it has acquired an Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar for the sale of Butorphanol Tartrate Nasal Spray, 10 mg/mL. Butorphanol is the generic equivalent to Bristol-Myers Squibb Company's Stadol(R) NS, which is indicated for the management of pain when an opoid analgesic is appropriate. Current annual sales for Stadol(R) NS are approximately $82 million. This product will be manufactured by a contract manufacturer and is available for immediate shipment from Mylan's Greensboro, North Carolina “Greensboro” redirects here. For other uses, see Greensboro (disambiguation). Greensboro, North Carolina (IPA: [ɡɹiːnsbʌɹəʊ]) is a city in the U.S. state of North Carolina. distribution center. Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL UDL Universal Design for Learning UDL Universitat de Lleida (Spain) UDL Universal Data Link UDL Urban Debate League UDL Uniformly Distributed Load (mechanics, building trade) UDL User Defined Logic Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. These products are manufactured and sold in a variety of dosage forms including immediate and extended-release oral tablets and capsules and transdermal patches as well as repackaging and marketing multi-source and single-source products in unit dose form. For more information, visit www.mylan.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion